Loading news...
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the stock in a transaction on Friday, January 9th. The shares were sold at an average price of $40.78, for a total value of $815,600.00. Following the completion of the transaction, the executive vice president owned 60,000 shares in the
Eastern Bank lifted its holdings in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 1,368.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 371,255 shares of the biopharmaceutical company's stock after purchasing an additional 345,968 shares during the quarter.
Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-‘408.
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board, will discuss these updates on January 13, 2026 as part of a webcast presentation to be held at 12:45 p.m. Eastern Time / 9:45 a.m. Pacific Time at the 44th Annual J.P. Morgan Healthcare Conference.
NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.
PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company's quarterly dividend over the previous quarter's dividend. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion.
Where Buffett's former heir apparent will invest $10 billion… exactly how to follow this blueprint… defense, aerospace, healthcare, energy, minerals, frontier tech… investment ideas from ETFs to single stocks
Generali Asset Management SPA SGR grew its holdings in Royalty Pharma PLC (NASDAQ: RPRX) by 7,752.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,081 shares of the biopharmaceutical company's stock after buying an additional 33,647 shares during the period. Generali
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the business's stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $39.32, for a total transaction of $786,400.00. Following the completion of the sale, the executive vice president directly owned
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and up to $60 million in sales-based milestones. Evrysdi, marketed by Roche, is an orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal muscular atrophy.
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP George Lloyd sold 79,346 shares of the firm's stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $38.57, for a total value of $3,060,375.22. Following the completion of the sale, the executive vice president directly owned 30,654 shares
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $38.32, for a total value of $766,400.00. Following the completion of the sale, the executive vice president directly owned 140,000 shares
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.
Eye-opening wealth data… a replay of this morning's "American Dream 2.0" Summit… where the government might point its investment firehose next… Eric Fry says where to invest beyond "AI"
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.